Optimal Duration of Anticoagulation in Deep Venous Thrombosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 584 participants.
Also called NCT01285661
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 584 participants
- Sponsor
- Registry
-
NCT01285661
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT01285661. Allocation not applicable; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Duration of Anticoagulation in Deep Venous Thrombosis
- Acronym
- MORGAGNI
- Condition
- Deep Vein Thrombosis of Lower Limb
- Condition
- Lower Extremity Deep Venous Thrombosis Recurrent
- Intervention (Drug)
- Sodium warfarin
- Lead sponsor
- University of Padova
Record details
- Record id
cardio:ct-nct01285661- Content hash
62375d9c751425c3f862050940e08ddbb6667c32e4642abdd1daaea3a8c89303